Claims

What is claimed is:

1. A compound of formula I:



I

or a pharmaceutically acceptable salt thereof wherein:

A is O,

NH, or

S;

B is

$C(=O)R_1$,

$C(=S)R_1$,

heterocylco,

heteroaryl,

C(=O)-heterocyclo, or

C(=O)-heteteroaryl;

D is N, E is C, F is CH, and " ------ " is a bond, or D is CH, E is N, F is CH_2, and " ------ " is absent;

P is



,



,



, or



, wherein "∿∿∿" indicates the point of attachment; and

is 5-membered heterocyclo or heteroaryl, wherein "∿∿∿" indicates points of attachment, and wherein the 5-membered heterocyclo or heteroaryl is optionally substituted with one or more group selected from aryl, heteroaryl, heterocyclo, OR_5, $OC(=O)R_1$, NR_6R_7, NR_5, $N(C=O)R_5$, $NH(C=O)OR_5$, $NHSO_2R_5$, $NHSO_2NR_5$, aryl, heteroaryl, heterocyclo, wherein aryl or heteroaryl is optionally substituted with one or more halo, OH, CF_3, CN, NO_2, $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $S(C_1\text{-}C_4)$alkyl, $C(=O)R_1$, OR_5, $OC(=O)R_1$, NR_6R_7, NHR_5, $N(C=O)R_5$, $NH(C=O)OR_5$, $NHSO_2R_5$, $NHSO_2NR_5$;

V and W independently are CH or N when "------"is absent; or are C when "------" is a bond;

X, Y, Z independently are O=C,

CH_2,

CHR_3,

CHR_4,

CR_3R_4,

NR_5,

$N(C=O)R_5$,

$N(C=O)OR_5$,

NSO_2R_5,

NSO_2NR_5,

O,

S,

SO, or

SO_2,

provided that at least one of X, Y, or Z is NR_5,

$N(C=O)R_5$,

$N(C=O)OR_5$,

NSO_2R_5,

NSO_2NR_5,

O,

S,

SO, or

SO_2;

J, K, Q independently are CR_2 or N, with the proviso that when any one of J, K, or Q is N, then the other two are CR_2;

R_1 is H,

$(C_1\text{-}C_8)$alkyl,

$(C_3\text{-}C_6)$cycloalkyl,

O—$(C_1\text{-}C_4)$alkyl,

O—$(C_3\text{-}C_6)$cycloalkyl,

S—$(C_1\text{-}C_4)$ alkyl,

S—$(C_3\text{-}C_6)$cycloalkyl,

NH_2,

$NH(C_1\text{-}C_4)$alkyl,

$N((C_1\text{-}C_4)\text{alkyl})_2$, or

NH—$(C_3\text{-}C_6)$cycloalkyl;

R_2 is H,
halo,
$(C_1$-$C_8)$alkyl,
$(C_3$-$C_6)$cycloalkyl,
O—$(C_1$-$C_4)$alkyl,
O—$(C_3$-$C_6)$cycloalkyl,
S—$(C_1$-$C_4)$ alkyl,
S—$(C_3$-$C_6)$cycloalkyl,
NH_2,
$NH(C_1$-$C_4)$alkyl,
$N((C_1$-$C_4)alkyl)_2$, or
NH—$(C_3$-$C_6)$cycloalkyl;

R_3 and R_4 independently are halo,
$(C_1$-$C_8)$alkyl,
$(C_3$-$C_6)$cycloalkyl,
O—$(C_1$-$C_4)$alkyl,
O—$(C_3$-$C_6)$cycloalkyl,
S—$(C_1$-$C_4)$ alkyl,
S—$(C_3$-$C_6)$cycloalkyl,
NH_2,
$NH(C_1$-$C_4)$alkyl,
$N((C_1$-$C_4)alkyl)_2$,
NH—$(C_3$-$C_6)$cycloalkyl;
aryl,
$(CH_2)_n$-aryl,
heterocyclo,
$(CH_2)_n$-heterocyclo,
heteroaryl, or
$(CH_2)_n$-heteroaryl;
wherein n is 0, 1, 2, or 3;

R_5 is H,

$(C_1\text{-}C_8)$alkyl,

$(C_3\text{-}C_6)$cycloalkyl,

aryl,

$(CH_2)_n$-aryl,

heterocyclo,

$(CH_2)_n$-heterocyclo,

heteroaryl, or

$(CH_2)_n$-heteroaryl;

wherein n is as defined above.

2. The compound of claim 1, wherein 

is



3. The compound of claim 1 as designated in formula IA.



IA

4. The compound of claim 1 as designated in formula IB.



IB

5. The compound of claim 1 as designated in formula IC.



IC

6. The compound of claim 5, wherein P is

 ,

 ,

 , or

 .

7. The compound of claim 6, wherein P is

 ,



,



, or



,

wherein J_a is N or CR_{10}, wherein R_{10} is H or F.and wherein only one or two of X, Y, or Z is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.

8. A compound of formula II



II

or a pharmaceutically acceptable salt thereof wherein:

A is O,

NH, or

S;

B is

$C(=O)R_1$,

$C(=S)R_1$,

heterocylco,

heteroaryl,

C(=O)-heterocyclo, or

C(=O)-heteteroaryl;

D is N, E is C, F is CH, and " ------ " is a bond, or D is CH, E is N, F is CH_2, and " ------ " is absent;

is 5-membered heterocyclo or heteroaryl, wherein " ∿∿∿ " indicates points of attachment, and wherein the 5-membered heterocyclo or heteroaryl is optionally substituted with one or more group selected from aryl, heteroaryl, heterocyclo, OR_5, $OC(=O)R_1$, NR_6R_7, NR_5, $N(C=O)R_5$, $NH(C=O)OR_5$, $NHSO_2R_5$, $NHSO_2NR_5$, aryl, heteroaryl, heterocyclo, wherein aryl or heteroaryl is optionally substituted with one or more halo, OH, CF_3, CN, NO_2, $(C_1$-$C_8)$alkyl, $(C_3$-$C_6)$cycloalkyl, $S(C_1$-$C_4)$alkyl, $C(=O)R_1$, OR_5, $OC(=O)R_1$, NR_6R_7, NHR_5, $N(C=O)R_5$, $NH(C=O)OR_5$, $NHSO_2R_5$, $NHSO_2NR_5$;

V and W independently are CH or N when " ------ "is absent; or are C when " ------ " is a bond;

X, Y, Z independently are O=C,

CH_2,

CHR_3,

CHR_4,

CR_3R_4,

NR_5,

$N(C=O)R_5$,

$N(C=O)OR_5$,

NSO_2R_5,

NSO_2NR_5,

O,

S,

SO, or

SO_2,

provided that at least one of X, Y, or Z is NR_5,

$N(C=O)R_5$,

$N(C=O)OR_5$,

NSO_2R_5,

NSO_2NR_5,

O,

S,

SO, or

SO_2;

J, K, Q independently are CR_2 or N, with the proviso that when any one of J, K, or Q is N, then the other two are CR_2;

R_1 is H,

$(C_1\text{-}C_8)$alkyl,

$(C_3\text{-}C_6)$cycloalkyl,

O—$(C_1\text{-}C_4)$alkyl,

O—$(C_3\text{-}C_6)$cycloalkyl,

S—$(C_1\text{-}C_4)$ alkyl,

S—$(C_3\text{-}C_6)$cycloalkyl,

NH_2,

$NH(C_1\text{-}C_4)$alkyl,

$N((C_1\text{-}C_4)\text{alkyl})_2$, or

NH—$(C_3\text{-}C_6)$cycloalkyl;

R_2 is H,

halo,

$(C_1\text{-}C_8)$alkyl,

$(C_3\text{-}C_6)$cycloalkyl,

O—(C_1-C_4)alkyl,
O—(C_3-C_6)cycloalkyl,
S—(C_1-C_4) alkyl,
S—(C_3-C_6)cycloalkyl,
NH_2,
NH(C_1-C_4)alkyl,
N((C_1-C_4)alkyl)$_2$, or
NH—(C_3-C_6)cycloalkyl;

R_3 and R_4 independently are halo,
(C_1-C_8)alkyl,
(C_3-C_6)cycloalkyl,
O—(C_1-C_4)alkyl,
O—(C_3-C_6)cycloalkyl,
S—(C_1-C_4) alkyl,
S—(C_3-C_6)cycloalkyl,
NH_2,
NH(C_1-C_4)alkyl,
N((C_1-C_4)alkyl)$_2$,
NH—(C_3-C_6)cycloalkyl;
aryl,
$(CH_2)_n$-aryl,
heterocyclo,
$(CH_2)_n$-heterocyclo,
heteroaryl, or
$(CH_2)_n$-heteroaryl;
wherein n is 0, 1, 2, or 3;

R_5 is H,
(C_1-C_8)alkyl,
(C_3-C_6)cycloalkyl,
aryl,

$(CH_2)_n$-aryl,

heterocyclo,

$(CH_2)_n$-heterocyclo,

heteroaryl, or

$(CH_2)_n$-heteroaryl;

wherein n is as defined above.

9. The compound of claim 9, wherein  is as defined in claim 2.

10. The compound of claim 9as designated in formula IIA.



IIA

11. The compound of claim 9 as designated in formula IIB.



IIB

12. The compound of claim 9 as designated in formula IIC.



IIC

13. The compound of claim 9 as designated in formula IID



IID

wherein J_a is N or CR_{10}, wherein R_{10} is H or F.and wherein only one or two of X, Y, or Z is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.

14. The compound of claim 9 as designated in formula IIE, wherein only one or two of X, Y, or Z is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.



IIE

15. The compound of claim 9 as designated in formula IIF, wherein X_a is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.



IIF

16. The compound of claim 9 as designated in formula IIG, wherein Y_a is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2..



IIG

17. The compound of claim 9 as designated in formula IIH, wherein Z_a is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.



IIH

18. A compound of formula III



III

or a pharmaceutically acceptable salt thereof wherein:

A is O,

NH, or

S;

B is

$C(=O)R_1$,

$C(=S)R_1$,

heterocylco,

heteroaryl,

C(=O)-heterocyclo, or

C(=O)-heteteroaryl;

D is N, E is C, F is CH, and " ------ " is a bond, or D is CH, E is N, F is CH_2, and " ------ " is absent;

is 5-membered heterocyclo or heteroaryl, wherein " ∿∿∿ " indicates points of attachment, and wherein the 5-membered heterocyclo or heteroaryl is optionally substituted with one or more group selected from aryl, heteroaryl, heterocyclo, OR_5, $OC(=O)R_1$, NR_6R_7, NR_5, $N(C=O)R_5$, $NH(C=O)OR_5$, $NHSO_2R_5$, $NHSO_2NR_5$, aryl, heteroaryl, heterocyclo, wherein aryl or heteroaryl is optionally substituted with one or more halo, OH, CF_3, CN, NO_2, $(C_1$-$C_8)$alkyl, $(C_3$-$C_6)$cycloalkyl, $S(C_1$-

C_4)alkyl, $C(=O)R_1$, OR_5, $OC(=O)R_1$, NR_6R_7, NHR_5, $N(C=O)R_5$, $NH(C=O)OR_5$, $NHSO_2R_5$, $NHSO_2NR_5$;

V and W independently are CH or N when "------"is absent; or are C when "------" is a bond;

X, Y, Z independently are O=C,

CH_2,

CHR_3,

CHR_4,

CR_3R_4,

NR_5,

$N(C=O)R_5$,

$N(C=O)OR_5$,

NSO_2R_5,

NSO_2NR_5,

O,

S,

SO, or

SO_2,

provided that at least one of X, Y, or Z is NR_5,

$N(C=O)R_5$,

$N(C=O)OR_5$,

NSO_2R_5,

NSO_2NR_5,

O,

S,

SO, or

SO_2;

J, K, Q independently are CR_2 or N, with the proviso that when any one of J, K, or Q is N, then the other two are CR_2;

R_1 is H,

$(C_1$-$C_8)$alkyl,

$(C_3$-$C_6)$cycloalkyl,

O—$(C_1$-$C_4)$alkyl,

O—$(C_3$-$C_6)$cycloalkyl,

S—$(C_1$-$C_4)$ alkyl,

S—$(C_3$-$C_6)$cycloalkyl,

NH_2,

$NH(C_1$-$C_4)$alkyl,

$N((C_1$-$C_4)alkyl)_2$, or

NH—$(C_3$-$C_6)$cycloalkyl;

R_2 is H,

halo,

$(C_1$-$C_8)$alkyl,

$(C_3$-$C_6)$cycloalkyl,

O—$(C_1$-$C_4)$alkyl,

O—$(C_3$-$C_6)$cycloalkyl,

S—$(C_1$-$C_4)$ alkyl,

S—$(C_3$-$C_6)$cycloalkyl,

NH_2,

$NH(C_1$-$C_4)$alkyl,

$N((C_1$-$C_4)alkyl)_2$, or

NH—$(C_3$-$C_6)$cycloalkyl;

R_3 and R_4 independently are halo,

$(C_1$-$C_8)$alkyl,

$(C_3$-$C_6)$cycloalkyl,

O—$(C_1$-$C_4)$alkyl,

O—$(C_3$-$C_6)$cycloalkyl,

S—$(C_1$-$C_4)$ alkyl,

S—(C_3-C_6)cycloalkyl,
NH_2,
NH(C_1-C_4)alkyl,
N((C_1-C_4)alkyl)$_2$,
NH—(C_3-C_6)cycloalkyl;
aryl,
$(CH_2)_n$-aryl,
heterocyclo,
$(CH_2)_n$-heterocyclo,
heteroaryl, or
$(CH_2)_n$-heteroaryl;

wherein n is 0, 1, 2, or 3;

R_5 is H,
(C_1-C_8)alkyl,
(C_3-C_6)cycloalkyl,
aryl,
$(CH_2)_n$-aryl,
heterocyclo,
$(CH_2)_n$-heterocyclo,
heteroaryl, or
$(CH_2)_n$-heteroaryl;

wherein n is as defined above.

19. The compound of claim 18, wherein 

is as defined in claim 2.

20. The compound of claim 18 as designated in formula IIIA.



IIIA

21. The compound of claim 19 as designated in formula IIIB.



IIIB

22. The compound of claim 19 as designated in formula IIIC.



IIIC

23. The compound of claim 19 as designated in formula IIID



IIID

wherein J_a is N or CR_{10}, wherein R_{10} is H or F.and wherein only one or two of X, Y, or Z is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.

24. The compound of claim 19 as designated in formula IIE, wherein only one or two of X, Y, or Z is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.



IIIE

25. The compound of claim 19 as designated in formula IIIF, wherein X_a is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2..



IIIF

26. The compound of claim 19 as designated in formula IIIG, wherein Y_a is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.



IIIG

27. The compound of claim 19 as designated in formula IIIH, wherein Z_a is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.



IIIH

28. A compound of formula IV:



IV

or a pharmaceutically acceptable salt thereof wherein:

A is O,

NH, or

S;

B is

$C(=O)R_1$,

$C(=S)R_1$,

heterocylco,

heteroaryl,

C(=O)-heterocyclo, or

C(=O)-heteteroaryl;

D is N, E is C, F is CH, and " ------ " is a bond, or D is CH, E is N, F is CH_2, and " ------ " is absent;

is 5-membered heterocyclo or heteroaryl, wherein " ∿∿∿∿ " indicates points of attachment, and wherein the 5-membered heterocyclo or heteroaryl is optionally substituted with one or more group selected from aryl, heteroaryl, heterocyclo, OR_5, $OC(=O)R_1$, NR_6R_7, NR_5, $N(C=O)R_5$, $NH(C=O)OR_5$, $NHSO_2R_5$, $NHSO_2NR_5$, aryl, heteroaryl, heterocyclo, wherein aryl or heteroaryl is optionally substituted with one or more halo, OH, CF_3, CN, NO_2, $(C_1$-$C_8)$alkyl, $(C_3$-$C_6)$cycloalkyl, $S(C_1$-$C_4)$alkyl, $C(=O)R_1$, OR_5, $OC(=O)R_1$, NR_6R_7, NHR_5, $N(C=O)R_5$, $NH(C=O)OR_5$, $NHSO_2R_5$, $NHSO_2NR_5$;

V and W independently are CH or N when " ------ "is absent; or are C when " ------ " is a bond;

X, Y, Z independently are O=C,

CH_2,

CHR_3,

CHR_4,

CR_3R_4,

NR_5,

$N(C=O)R_5$,

$N(C=O)OR_5$,

NSO_2R_5,

NSO_2NR_5,

O,

S,

SO, or

SO_2,

provided that at least one of X, Y, or Z is NR_5,

$N(C=O)R_5$,

$N(C=O)OR_5$,

NSO_2R_5,

NSO_2NR_5,

O,

S,

SO, or

SO_2;

J, K, Q independently are CR_2 or N, with the proviso that when any one of J, K, or Q is N, then the other two are CR_2;

R_1 is H,

$(C_1\text{-}C_8)$alkyl,

$(C_3\text{-}C_6)$cycloalkyl,

O—$(C_1\text{-}C_4)$alkyl,

O—$(C_3\text{-}C_6)$cycloalkyl,

S—$(C_1\text{-}C_4)$ alkyl,

S—$(C_3\text{-}C_6)$cycloalkyl,

NH_2,

$NH(C_1\text{-}C_4)$alkyl,

$N((C_1\text{-}C_4)\text{alkyl})_2$, or

NH—$(C_3\text{-}C_6)$cycloalkyl;

R_2 is H,

halo,

$(C_1\text{-}C_8)$alkyl,

$(C_3\text{-}C_6)$cycloalkyl,

O—$(C_1\text{-}C_4)$alkyl,

O—$(C_3\text{-}C_6)$cycloalkyl,

S—$(C_1\text{-}C_4)$ alkyl,

S—(C_3-C_6)cycloalkyl,
NH_2,
NH(C_1-C_4)alkyl,
N((C_1-C_4)alkyl)$_2$, or
NH—(C_3-C_6)cycloalkyl;

R_3 and R_4 independently are halo,
(C_1-C_8)alkyl,
(C_3-C_6)cycloalkyl,
O—(C_1-C_4)alkyl,
O—(C_3-C_6)cycloalkyl,
S—(C_1-C_4) alkyl,
S—(C_3-C_6)cycloalkyl,
NH_2,
NH(C_1-C_4)alkyl,
N((C_1-C_4)alkyl)$_2$,
NH—(C_3-C_6)cycloalkyl;
aryl,
$(CH_2)_n$-aryl,
heterocyclo,
$(CH_2)_n$-heterocyclo,
heteroaryl, or
$(CH_2)_n$-heteroaryl;
wherein n is 0, 1, 2, or 3;

R_5 is H,
(C_1-C_8)alkyl,
(C_3-C_6)cycloalkyl,
aryl,
$(CH_2)_n$-aryl,
heterocyclo,
$(CH_2)_n$-heterocyclo,

heteroaryl, or

$(CH_2)_n$-heteroaryl;

wherein n is as defined above.

29. The compound of claim 28, wherein  is as defined in claim 2.

30. The compound of claim 28 as designated in formula IVA.



IVA

31. The compound of claim 28 as designated in formula IVB.



IVB

32. The compound of claim 28 as designated in formula IVC.



IVC

33. The compound of claim 28 as designated in formula IVD



IVD

wherein J_a is N or CR_{10}, wherein R_{10} is H or F.and wherein only one or two of X, Y, or Z is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.

34. The compound of claim 28 as designated in formula IVE, wherein only one or two of X, Y, or Z is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.



IVE

wherein R_8 and R_9 are each independently H; halo, $(C_1\text{-}C_8)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, O—$(C_1\text{-}C_4)$ alkyl, S—$(C_1\text{-}C_4)$ alkyl, aryl, $(CH_2)_n$-aryl, heterocyclo, $(CH_2)_n$-heterocyclo, heteroaryl, or $(CH_2)_n$-heteroaryl, wherein n is 0, 1, 2, or 3; or taken together R_8 and R_9 are bonded to the same C and form C=O.

35. The compound of claim 28 as designated in formula IVF, wherein X_a is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2..



IVF

36. The compound of claim 28 as designated in formula IVG, wherein Y_a is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.



IVG

37. The compound of claim 28 as designated in formula IVH, wherein Z_a is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.



IVH

38. A compound of formula V:



V

or a pharmaceutically acceptable salt thereof wherein:

A is O,

NH, or

S;

B is

$C(=O)R_1$,

$C(=S)R_1$,

heterocylco,

heteroaryl,

C(=O)-heterocyclo, or

C(=O)-heteteroaryl;

D is N, E is C, F is CH, and " ------ " is a bond, or D is CH, E is N, F is CH_2, and " ------ " is absent;

is 5-membered heterocyclo or heteroaryl, wherein " ∿∿∿ " indicates points of attachment, and wherein the 5-membered heterocyclo or heteroaryl is optionally substituted with one or more group selected from aryl, heteroaryl, heterocyclo, OR_5, $OC(=O)R_1$, NR_6R_7, NR_5, $N(C=O)R_5$, $NH(C=O)OR_5$, $NHSO_2R_5$, $NHSO_2NR_5$, aryl, heteroaryl, heterocyclo, wherein aryl or heteroaryl is optionally substituted with one or more halo, OH, CF_3, CN, NO_2, $(C_1$-$C_8)$alkyl, $(C_3$-$C_6)$cycloalkyl, $S(C_1$-$C_4)$alkyl, $C(=O)R_1$, OR_5, $OC(=O)R_1$, NR_6R_7, NHR_5, $N(C=O)R_5$, $NH(C=O)OR_5$, $NHSO_2R_5$, $NHSO_2NR_5$;

V and W independently are CH or N when " ------ "is absent; or are C when " ------ " is a bond;

X, Y, Z independently are O=C,

CH_2,

CHR_3,

CHR_4,

CR_3R_4,

NR_5,

$N(C=O)R_5$,

$N(C=O)OR_5$,

NSO_2R_5,

NSO_2NR_5,

O,

S,

SO, or

SO_2,

provided that at least one of X, Y, or Z is NR_5,

$N(C=O)R_5$,

$N(C=O)OR_5$,

NSO_2R_5,

NSO_2NR_5,

O,

S,

SO, or

SO_2;

J, K, Q independently are CR_2 or N, with the proviso that when any one of J, K, or Q is N, then the other two are CR_2;

R_1 is H,

$(C_1\text{-}C_8)$alkyl,

$(C_3\text{-}C_6)$cycloalkyl,

O—$(C_1\text{-}C_4)$alkyl,

O—$(C_3\text{-}C_6)$cycloalkyl,

S—(C_1-C_4) alkyl,
S—(C_3-C_6)cycloalkyl,
NH_2,
NH(C_1-C_4)alkyl,
N((C_1-C_4)alkyl)$_2$, or
NH—(C_3-C_6)cycloalkyl;

R_2 is H,
halo,
(C_1-C_8)alkyl,
(C_3-C_6)cycloalkyl,
O—(C_1-C_4)alkyl,
O—(C_3-C_6)cycloalkyl,
S—(C_1-C_4) alkyl,
S—(C_3-C_6)cycloalkyl,
NH_2,
NH(C_1-C_4)alkyl,
N((C_1-C_4)alkyl)$_2$, or
NH—(C_3-C_6)cycloalkyl;

R_3 and R_4 independently are halo,
(C_1-C_8)alkyl,
(C_3-C_6)cycloalkyl,
O—(C_1-C_4)alkyl,
O—(C_3-C_6)cycloalkyl,
S—(C_1-C_4) alkyl,
S—(C_3-C_6)cycloalkyl,
NH_2,
NH(C_1-C_4)alkyl,
N((C_1-C_4)alkyl)$_2$,
NH—(C_3-C_6)cycloalkyl;
aryl,

$(CH_2)_n$-aryl,

heterocyclo,

$(CH_2)_n$-heterocyclo,

heteroaryl, or

$(CH_2)_n$-heteroaryl;

wherein n is 0, 1, 2, or 3;

R_5 is H,

$(C_1\text{-}C_8)$alkyl,

$(C_3\text{-}C_6)$cycloalkyl,

aryl,

$(CH_2)_n$-aryl,

heterocyclo,

$(CH_2)_n$-heterocyclo,

heteroaryl, or

$(CH_2)_n$-heteroaryl;

wherein n is as defined above.

39. The compound of claim 38, wherein 

is as defined in claim 2.

40. The compound of claim 38 as designated in formula VA.



VA

41. The compound of claim 38 as designated in formula VB.



VB

42. The compound of claim 38 as designated in formula VC.



VC

43. The compound of claim 38 as designated in formula VD



VD

wherein J_a is N or CR_{10}, wherein R_{10} is H or F.and wherein only one or two of X, Y, or Z is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.

44. The compound of claim 38 as designated in formula IIE, wherein only one or two of X, Y, or Z is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.



VE

45. The compound of claim 38 as designated in formula VF, wherein X_a is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2..



VF

46. The compound of claim 38 as designated in formula VG, wherein Y_a is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.



VG

47. The compound of claim 38 as designated in formula VH, wherein Z_a is NR_5, $N(C=O)R_5$, $N(C=O)OR_5$, NSO_2R_5, NSO_2NR_5, O, S, SO, or SO_2.



49. A compound which is:

(S)-N-[3-(4,5-Dihydro-2H-6-oxa-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(2-Methyl-4,5-dihydro-2H-6-oxa-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(1-Methyl-4,5-dihydro-1H-6-oxa-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(2-Ethyl-4,5-dihydro-2H-6-oxa-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(1-Ethyl-4,5-dihydro-1H-6-oxa-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(2-Benzyl-4,5-dihydro-2H-6-oxa-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(1-Benzyl-4,5-dihydro-1H-6-oxa-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[2-Oxo-3-(2-phenethyl-4,5-dihydro-2H-6-oxa-1,2-diaza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[2-Oxo-3-(1-phenethyl-4,5-dihydro-1H-6-oxa-1,2-diaza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[2-Oxo-3-(3-phenyl-4,5-dihydro-2H-6-oxa-1,2-diaza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(2,6-Dihydro-4H-5-oxa-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(5,6-Dihydro-2H-4-oxa-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[2-Oxo-3-(2,4,5,6-tetrahydro-1,2,6-triaza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[2-Oxo-3-(2,4,5,6-tetrahydro-1,2,5-triaza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[2-Oxo-3-(2,4,5,6-tetrahydro-1,2,4-triaza-benzo[e]azulen-8-yl)-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(4,5-Dihydro-2H-6-thia-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(2,6-Dihydro-4H-5-thia-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(5,6-Dihydro-2H-4-thia-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(6,6-Dioxo-2,4,5,6-tetrahydro-6l6-thia-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(5,5-Dioxo-2,4,5,6-tetrahydro-5l6-thia-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(4,4-Dioxo-2,4,5,6-tetrahydro-4l6-thia-1,2-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(4,5-Dihydro-1,6-dioxa-2-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(4H,6H-1,5-Dioxa-2-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(5,6-Dihydro-1,4-dioxa-2-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(5,6-Dihydro-4H-1-oxa-2,6-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(5,6-Dihydro-4H-1-oxa-2,5-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(5,6-Dihydro-4H-1-oxa-2,4-diaza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(4,5-Dihydro-1-oxa-6-thia-2-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(4H,6H-1-Oxa-5-thia-2-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(5,6-Dihydro-1-oxa-4-thia-2-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(4,5-Dihydro-1-oxa-6-thia-2-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide;

(S)-N-[3-(5,5-Dioxo-5,6-dihydro-4H-1-oxa-5l6-thia-2-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide; or

(S)-N-[3-(5,6-Dihydro-1-oxa-4-thia-2-aza-benzo[e]azulen-8-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide.

50. A pharmaceutical formulation comprising a compound of claim 1 admixed with a pharmaceutically acceptable diluent, carrier, or excipient.

51. A method of treating a bacterial infection in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound of claim 1.